Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Molecular Pair Identified as Key to Host-Cell Invasion by Tick-Transmitted Pathogen

By BiotechDaily International staff writers
Posted on 22 Oct 2012
Print article
Image: Two Anaplasma phagocytophilum bacteria (arrows) bound to host cell surfaces; the bacterium on the right (thick arrow) is invading upon triggering its own uptake. (Photo courtesy of Jason Carlyon, PhD, and Matthew J. Troese, PhD / VCU.)
Image: Two Anaplasma phagocytophilum bacteria (arrows) bound to host cell surfaces; the bacterium on the right (thick arrow) is invading upon triggering its own uptake. (Photo courtesy of Jason Carlyon, PhD, and Matthew J. Troese, PhD / VCU.)
A pathogen-host “key and door” molecular pair has been identified as critical for the cell-cell adhesion required for invasion by the tick-transmitted pathogen Anaplasma phagocytophilum. The finding provides an important candidate target for development of drugs and a single vaccine against diseases caused by this and closely related pathogens.

A. phagocytophilum is an Anaplasmataceae family bacterium responsible for causing granulocytic anaplasmosis in humans; other tick-transmitted Anaplasmataceae species often cause diseases in domestic and livestock animals, including cattle. From studies in vitro using mammalian cell cultures and in vivo using mice, scientists at the Virginia Commonwealth University (VCU; Richmond, VA, USA) School of Medicine have shown that “outer membrane protein A” (OmpA) on the surface of A. phagocytophilum is critically important for its invasion of host cells. They also delineated a specific region in OmpA that mediates infection and is conserved among Anaplasmataceae family species. The research team showed that OmpA binds mammalian host cell surface sialylated glycoproteins and confirmed that this interaction is important for the adhesion stage of infection. "In other words, we identified both a key and door that together promote Anaplasma phagocytophilum infection," said lead investigator Jason A. Carlyon, PhD, associate professor, and a George and Lavinia Blick Scholar in the Department of Microbiology and Immunology of the VCU School of Medicine. "These findings are important because our data also establish a direction for development of a single vaccine that protects against members of an entire family of bacteria that cause disease," he added.

The study published online and planned to appear in print in the November 2012 issue of the journal Infection and Immunity (volume 80, issue 11), identifies the first A. phagocytophilum adhesin-receptor pair, and delineates the region of OmpA that is critical for infection. Researchers in Prof. Carlyon's laboratory are presently refining their understanding of the molecular basis for how OmpA promotes infection and are testing its efficacy in protecting against infection by A. phagocytophilum and other pathogenenic Anaplasmataceae members.

Related Links:
Virginia Commonwealth University



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.